The Ecodas by PRI™ BIOXstream™ hybrid autoclave system gives you the ability to sterilize your single-use bioprocessing assemblies onsite, reducing monthly treatment service costs, rendering the material common municipal waste, for disposal or recycle.
Pharmaceutical companies are continuously streamlining processes to reduce their carbon footprint. The development of single-use biopharmaceutical processing was a step in the right direction, reducing the amount of water, chemicals, and energy required for cleaning validation.
Now, pharmaceutical companies are taking efficiency a step further. In recent years, Biogen, Genentech, Johnson & Johnson, Novartis, and Patheon signed the American Business Act on Climate Pledge declaring their goals. The BioXstream™ supports these ongoing initiatives, reducing your carbon footprint, energy and waste to landfill.
The BIOXstream™ on-site treatment system offers a green shift in the way single-use biopharmaceutical waste is handled, treated and disposed of. With BioXstream™, waste can be treated before it ever leaves the pharmaceutical facility. This delivers a significant savings and ROI over current methods, and gives you the ability to maintain control over your waste, reducing risks and liability, while reducing the environmental impact: